Søgning på udtrykket 'remdesivir' giver 34 resultater


Dokumenter [3] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [11]

Dokumenter [3]

Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: 1. Et af Paxlovid kriterierne ændret (fra ”Betydelige symptomer på COVID-19” til ”Mild eller moderat COVID-19”). 2. Døde links til infektionshygiejniske retningslinjer er fjernet, og nyt er indsat. 3. Tekst om afisolation.

DSI anbefaler fortsat remdesivir ved indlæggelsekrævende COVID-19 med behov for tilskud af ilt, hvor iltmætningen i blodet er under 94% uden ilttilskud hos ellers lungeraske og, at hvor der ved røntgen af thorax påvises infiltrat(er). Dette holdningspapir omhandler baggrunden for anbefalingen.

Denne vejledning er tiltænkt diagnostik og behandling af COVID-19. Denne retningslinje vil løbende blive opdateret, som ny evidens kommer frem. Der er ikke foretaget en gradering af evidensniveau. Ændringer i denne udgave: Remdesivir står ikke længere som relativt kontraindiceret ved påvirket nyrefunktion.

Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
BMC Infectious Diseases
2.01.2024
. Abstract. . Background. The health crisis due to Covid-19 led to the search for therapeutics that could improve the evolution of the disease. Remdesivir, an antiviral that interferes with viral replication, was one of the first to be used for the treatment of this pathology. . . . Objective. To determine clinical course and mortality of pa…
BMC Infectious Diseases
10.10.2023
. Abstract. . Background. Remdesivir is considered to be a specific drug for treating coronavirus disease 2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs. . . . Research design and methods. The PubMed, Embase, SCIE, Cochrane Library, and American Clinical tr…
Lancet Respiratory Medicine
31.08.2023
Among patients with COVID-19-associated acute hypoxaemic respiratory failure, aviptadil did not significantly improve clinical outcomes up to day 90 when compared with placebo. The smaller than planned sample size for the remdesivir trial did not permit definitive conclusions regarding safety or efficacy.
Clinical Infectious Diseases
10.08.2023
…ocompromised patients are at high risk of severe COVID-19 and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. This comparative effectiveness study investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods.MethodsData for immunocompromised patients hospitalized for COVID-19 between December 2020 and April 2022 we…
Journal of Medical Virology
5.08.2023
Journal of Medical Virology, Volume 95, Issue 8, August 2023.
Journal of Infectious Diseases
21.07.2023
AbstractBackgroundUncertainty over the therapeutic benefit provided by parenteral remdesivir in COVID-19 has resulted in varying treatment guidelines.MethodsIn a multicenter open label, controlled, adaptive, pharmacometric platform trial, low-risk adult patients with early symptomatic COVID-19 were randomized to one of eight treatment arms including intravenous remdesivir (200 mg followed by 100 mg daily for five days) or no study drug. The primary outcome was the rate of viral clearance (estimated unde…
Journal of Infectious Diseases
19.07.2023
AbstractBackgroundRemdesivir is approved for the treatment of COVID-19 in non-hospitalized and hospitalized adult and pediatric patients. Here we present SARS-CoV-2 resistance analyses from the Phase 3 ACTT-1 randomized placebo-controlled trial conducted in adult participants hospitalized with COVID-19.MethodsSwab samples were collected at baseline and longitudinally through Day 29. SARS-CoV-2 genomes were sequenced using next-generation sequencing. Phenotypic analysis was conducted directly on participant …
BMC Infectious Diseases
12.07.2023
. Abstract. . Background. Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. . . . Methods. This retrospective observational multicenter study included consec…
BMC Infectious Diseases
9.07.2023
. Abstract. . Background. Remdesivir is widely used for treatment of SARS-CoV-2 pneumonia. The aim of this study was to evaluate the characteristics of patients with moderate-to-severe COVID-19 treated with remdesivir, and their outcomes during hospitalization. . . . Methods. This retrospective observational multicenter study included consec…
BMJ Open
10.06.2023
. Objectives. This study investigated remdesivir’s clinical use to provide direct evidence of effectiveness for a low-middle income Asian setting. . Design. A one-to-one propensity score matching retrospective cohort study. . Setting. A tertiary hospital with COVID-19 treatment facilities in Vietnam. . Participants. A total of 310 patients in standard of care (SoC) group were matched with 310 patients in SoC+remdesivir (SoC+R) group. . Primary and secondary outcome measures. The primary outcome was ti…
BMC Infectious Diseases
5.05.2023
. Abstract. . Background. Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. . . . Methods. We conducted …
Lancet Respiratory Medicine
4.05.2023
This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir. The effect size of remdesivir in patients with more respiratory support or acquired immunity and the cost-effectiveness of remdesivir remain to be further elucidated.
Infection
12.02.2023
. Abstract. . Objectives. The use of remdesivir (RDV) as the first drug approved for coronavirus disease 2019 (COVID-19) remains controversial. Based on the Lean European Open Survey on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected patients (LEOSS), we aim to contribute timing-focused complementary real-world insights to its evaluation. . . Methods. …
International Journal of Infectious Diseases
19.01.2023
Georgia introduced remdesivir for the treatment of coronavirus disease 2019 (COVID-19) in December 2020. We evaluated the real-world effect of remdesivir on mortality and the need for mechanical ventilation among COVID-19 inpatients.
International Journal of Infectious Diseases
12.12.2022
: Access and appropriateness of therapeutics for COVID-19 vary due to access or regulatory barriers, severity of disease, and for some therapies, stage of the pandemic and circulating variants. Remdesivir has shown benefits in clinical recovery and is the treatment of choice for selected patients, both hospitalized and non-hospitalized, in main international guidelines. The use of Remdesivir in alternatives to conventional hospitalization such as Hospital at Home units remain incompletely explored.
Clinical Infectious Diseases
26.10.2022
AbstractA patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, IV remdesivir and prolonged oral steroids. Twenty days of nirmatrelvir/ritonavir and 10 days of IV remdesivir led to full recovery.

Aktuelle smitsomme sygdomme [11]

Medscape Infectious Diseases
29.08.2023
The move is important because, previously, some people with liver disease had limited treatment options for severe cases of COVID-19. . WebMD Health News
Medscape Infectious Diseases
23.12.2021
The study determined the risk of hospitalization or death was 87% lower in study participants who were given remdesivir than participants who received a placebo. .
Medscape Infectious Diseases
22.09.2021
In a phase 3 trial, remdesivir was linked with an 87% reduction in COVID-19-related hospitalization or all-cause death compared with placebo.
Medscape Infectious Diseases
15.07.2021
Investigators studied VA patients with COVID-19 to determine what effect the antiviral might have on hospital stay and survival.
Medscape Infectious Diseases
11.06.2021
A causal relationship between COVID-19 treatment with remdesivir and sinus bradycardia is 'at least a reasonable possibility,' the EMA's safety committee has concluded.
ProMED
26.03.2021
COVID-19 -- Worldwide/UnknownWHO region (no. countries/territories):Total confirmed cases (new cases in last 24 hours) / Total deaths (new deaths in last 24 hours)--------------------------------------------------------------------------------Western Pacific Region (19): 1 818 355 (11 116) / 31 116 (82)European Region (61): 43 403 111 (256 686) / 944 129 (3706)South East Asia Region (10): 14 407 130 (62 949) / 216 373 (395)Eastern Mediterranean Region (22): 7 280 410 (37 424) / 155 448 (453)Region of the
Medscape Infectious Diseases
23.12.2021
The study determined the risk of hospitalization or death was 87% lower in study participants who were given remdesivir than participants who received a placebo. .
Medscape Infectious Diseases
22.09.2021
In a phase 3 trial, remdesivir was linked with an 87% reduction in COVID-19-related hospitalization or all-cause death compared with placebo.
Medscape Infectious Diseases
11.06.2021
A causal relationship between COVID-19 treatment with remdesivir and sinus bradycardia is 'at least a reasonable possibility,' the EMA's safety committee has concluded.

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2024 Dansk Selskab for Infektionsmedicin

CVR: 33634307

www.infmed.dk
Version: 2.12.2
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 0.855 s

Cookies og privatliv